Hepatocellular Carcinoma: Durvalumab and Bevacizumab Combination Almost Doubles Progression-Free Survival
A groundbreaking randomized trial has showcased significant advancements in systemic therapy for unresectable liver cancer. The addition of durvalumab (Imfinzi) and bevacizumab (Avastin) to transarterial chemoembolization (TACE) has nearly doubled the median progression-free survival (PFS) for patients. The EMERALD-1 trial demonstrated that individuals receiving this combination had a median PFS of 15.0 months compared to … Read more